Case Study in IBS-C

A Case Study in the IBS-C Management Continuum: Assessing Patient Response and Tailoring Treatment

Patient Case A 60-year-old woman presented to the clinic with a chief complaint of constipation (Table 1). She reported that she had been experiencing altered bowel […]

Feature

Clinical Guide to Navigating the Landscape of Biosimilars for Inflammatory Bowel Disease

Abstract: Annual out-of-pocket expenditures for patients with inflammatory bowel disease (IBD) are estimated to be as high as $41,000, with medications, such as biologics, being one […]

Advances in GERD

Adverse Events Associated With Proton Pump Inhibitors: Fact vs Fiction

G&H  What is known about the safety of proton pump inhibitors? PM  Historically, proton pump inhibitors (PPIs) have been regarded as highly safe. For any disease […]

HCC in Focus

Update on Hepatocellular Carcinoma Surveillance, Staging, and Therapy

G&H  What are the latest recommendations for hepatocellular carcinoma surveillance? SE  All patients with cirrhosis from any cause and those with hepatitis B who are noncirrhotic, […]

Advances in Hepatology

Current Management of Patients With Alcohol-Associated Hepatitis

G&H  How has alcohol use changed since the COVID-19 pandemic?  BL  Heavy alcohol use had been declining before the COVID-19 pandemic. The pandemic saw a significant […]

Advances in IBD

Positioning Sphingosine-1 Phosphate Receptor Modulators in Inflammatory Bowel Disease

G&H What was the rationale for first considering sphingosine-1 phosphate receptor modulators as a treatment approach for inflammatory bowel disease? BS Biologic therapies have revolutionized the […]

July 2024

Letter From the Editor

Letter From the Editor: Exploring the Use of Biosimilars to Treat Patients With Inflammatory Bowel Disease

How and when should biosimilars be used to treat patients with inflammatory bowel disease (IBD)? With more than 10 infliximab and adalimumab biosimilars now available in […]